Echo IQ Limited has secured a binding Heads of Agreement with Pro Medicus Limited, establishing a strategic investment and US commercial partnership worth up to A$20 million. Pro Medicus will invest an initial A$10 million, with an option to invest a further A$10 million contingent on FDA clearance of Echo IQ’s EchoSolv HF product. This development represents a significant validation of Echo IQ’s artificial intelligence-powered cardiac diagnostic technology and a major step in accelerating the company’s US market penetration.
The partnership structure is notably strategic. Rather than a simple funding round, Pro Medicus is committing to become a reseller of EchoSolv across the United States, leveraging its extensive network of leading health systems, academic medical centres, and enterprise healthcare customers. This dual commitment ties Pro Medicus’ participation directly to a key value catalyst for Echo IQ, as the second tranche of funding is explicitly conditioned on FDA clearance. The arrangement demonstrates confidence from one of Australia’s most successful healthcare technology companies in both the clinical utility and commercial potential of Echo IQ’s solution.
For investors, this announcement addresses several critical challenges that early-stage medical device companies typically face. Echo IQ now has secured funding to accelerate US commercialisation activities and has obtained validation from a respected healthcare technology platform with proven market access and customer relationships. Pro Medicus brings not just capital but also infrastructure and distribution networks that would have taken Echo IQ years to develop independently. The timing is particularly important as Echo IQ works towards FDA clearance for EchoSolv HF, which the company notes remains on track for an outcome in the near term.
The conditional nature of the second tranche creates an interesting dynamic for monitoring. Investors should track FDA clearance progress closely, as achieving this milestone would unlock the additional A$10 million and validate Pro Medicus’ assessment of the technology’s commercial potential. The binding HOA suggests both parties are confident enough in the relationship to commit to its framework, with definitive legal documentation expected to be finalised in the coming weeks. Once completed, this transaction will provide Echo IQ with full funding to support its US commercialisation strategy.
Echo IQ’s approach of securing partnership with an established healthcare technology leader aligns with how successful medical device companies typically scale internationally. Rather than building US infrastructure from scratch, the company is leveraging Pro Medicus’ platform and customer base to accelerate adoption. This model has proven effective across biotech and medical technology sectors. The announcement underscores that Echo IQ’s clinical positioning and commercial potential have attracted serious attention from institutional players in healthcare technology.
Key milestones for investors to monitor are the completion of definitive legal documentation expected in the coming weeks and the FDA clearance timeline for EchoSolv HF. The conditional funding structure means that FDA approval becomes a critical value inflection point for the company. This announcement has been flagged as price sensitive by the ASX.
View the full ASX announcement (PDF)
About Pro Medicus Limited (ASX: PME)
Pro Medicus Limited is an Australian health imaging software company headquartered in Victoria that develops advanced diagnostic imaging solutions for the global healthcare market. The company’s main business segment centers on its Visage imaging platform, a viewer and analysis solution used by hospitals and medical institutions to manage and interpret medical images. Pro Medicus operates primarily through its U.S. subsidiary Visage Imaging, Inc., serving major healthcare systems across North America and internationally on a transaction-based licensing model.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
